106 related articles for article (PubMed ID: 16557205)
1. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients.
Santiago JF; Gonen M; Yeung H; Macapinlac H; Larson S
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):61-7. PubMed ID: 16557205
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera.
Andrieux A; Switsers O; Chajari MH; Jacob JH; Delozier T; Gervais R; Allouache N; Laurençon V; Henry-Amar M; Bardet S
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):68-77. PubMed ID: 16557206
[TBL] [Abstract][Full Text] [Related]
3. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
4. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
5. Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study.
Pepe G; Rossetti C; Sironi S; Landoni C; Gianolli L; Pastorino U; Zannini P; Mezzetti M; Grimaldi A; Galli L; Messa C; Fazio F
Nucl Med Commun; 2005 Sep; 26(9):831-7. PubMed ID: 16096588
[TBL] [Abstract][Full Text] [Related]
6. PET/CT and breast cancer.
Zangheri B; Messa C; Picchio M; Gianolli L; Landoni C; Fazio F
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S135-42. PubMed ID: 15133636
[TBL] [Abstract][Full Text] [Related]
7. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
8. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.
Eubank WB; Mankoff D; Bhattacharya M; Gralow J; Linden H; Ellis G; Lindsley S; Austin-Seymour M; Livingston R
AJR Am J Roentgenol; 2004 Aug; 183(2):479-86. PubMed ID: 15269044
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.
Uematsu T; Kasami M; Yuen S
Breast Cancer; 2009; 16(2):97-104. PubMed ID: 18663562
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET in monitoring therapy of breast cancer.
Biersack HJ; Bender H; Palmedo H
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S112-7. PubMed ID: 15112111
[TBL] [Abstract][Full Text] [Related]
12. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management.
Chan SC; Yen TC; Ng SH; Lin CY; Wang HM; Liao CT; Fan KH; Chang JT
J Nucl Med; 2006 Sep; 47(9):1447-54. PubMed ID: 16954552
[TBL] [Abstract][Full Text] [Related]
14. The role of FDG-PET/CT in suspected recurrence of breast cancer.
Radan L; Ben-Haim S; Bar-Shalom R; Guralnik L; Israel O
Cancer; 2006 Dec; 107(11):2545-51. PubMed ID: 17063499
[TBL] [Abstract][Full Text] [Related]
15. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome.
Tran A; Pio BS; Khatibi B; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Sep; 46(9):1455-9. PubMed ID: 16157527
[TBL] [Abstract][Full Text] [Related]
17. Early clinical experience and impact of 18F-FDG PET.
Gutte H; Højgaard L; Kjaer A
Nucl Med Commun; 2005 Nov; 26(11):989-94. PubMed ID: 16208177
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
20. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
